DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
Oncology Drugs Experience Sales Slowdown In U.S.
Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
China Analyst Identifies 10 Pharma Stocks with Highest Growth Potential
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
Brain Cancer Vaccine Extends Survival Rate In Small Trial
A brain cancer vaccine from Immunocellular Therapeutics has yielded positive results in a small Phase I clinical trial.
Immune-Based Treatments for Brain Cancer Post Impressive Early-Stage Results
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
CytRx Puts Its Cancer Pipeline to the Test
All told, the Los Angeles-based company could have six to eight trials running simultaneously in the coming months.
ProtoxPresents Data, Awaits Key Results for PRX302
Protox Therapeutics applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer.
Sen. Kennedy Death Puts Focus On Brain Cancer
Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy’s life, is one of the deadliest brain tumors that can occur in both adults and children.
